Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

Fig. 2

Kaplan-Meier analysis of time to metastasis (TTM) as displayed by PIK3CA mutation status (a); by aspirin use (b); and by combined aspirin use and PIK3CA mutation status (c). Kaplan-Meier analysis of time 6 months post primary diagnosis to death as displayed by PIK3CA mutation status (d); by aspirin use (e); and by combined aspirin use and PIK3CA mutation status (f)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us